Drug Reduces Fracture Risk in Men with Heart Failure
Spironolactone already shown to preserve skeletal strength in animal study
TUESDAY, July 1 (HealthDay News) -- Spironolactone, which has been shown to preserve skeletal strength in animals, is associated with a reduced risk of fracture in men with congestive heart failure, according to a report in the July 8 issue of the Journal of the American College of Cardiology.
Laura J. Carbone, M.D., and colleagues from the University of Tennessee Health Science Center in Memphis, reviewed the medical records of 4,735 men with congestive heart failure treated at a Veterans Affairs Medical Center to identify men with single-incident fracture.
The researchers identified 167 men with fractures and 668 matched controls without fractures. After adjusting for several factors, the investigators found that spironolactone use (mean dose 25 mg/day) significantly reduced the risk of total fracture (odds ratio, 0.575). There was no significant association for hip or wrist fractures, but there was a significant association for vertebral fractures (OR, 0.581) and fractures at other sites (OR, 0.236). Longer use of spironolactone (over six months) reduced fracture risk more than shorter use, the report indicates.
"The use of spironolactone is inversely associated with fractures in men with congestive heart failure," Carbone and colleagues conclude.